Appili Therapeutics Inc
TSX:APLI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Appili Therapeutics Inc
TSX:APLI
|
CA |
|
I
|
Intelligentias Inc
OTC:ITLI
|
US |
|
H
|
Hotel Fitra International Tbk PT
IDX:FITT
|
ID |
|
C
|
Candles Scandinavia AB
STO:CANDLE B
|
SE |
|
N
|
Northern Lion Gold Corp
XTSX:NL
|
CA |
|
Pure Energy Minerals Ltd
XTSX:PE
|
CA |
|
Heineken NV
F:HNK2
|
NL |
|
Enensys Technologies SA
F:20U
|
FR |
Appili Therapeutics Inc
Appili Therapeutics, Inc. is a pharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2019-06-25. The firm is focused on the acquisition and development of medicines targeting infectious disease. The firm also focused on building and advancing a diverse portfolio of anti-infective programs. Its anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is used for the treatment of invasive fungal infections with a near-term focus on those caused by Cryptococcus and Candida. The ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The ATI-1503 is a drug discovery program builds off the molecular structure of negamycin, a naturally occurring compound that can kill Gram-negative bacteria. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole. Metronidazole is a front-line antibiotic for the treatment of anaerobic bacterial and parasitic infections. The Favipiravir is an oral covid-19 antiviral candidate.
Appili Therapeutics, Inc. is a pharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2019-06-25. The firm is focused on the acquisition and development of medicines targeting infectious disease. The firm also focused on building and advancing a diverse portfolio of anti-infective programs. Its anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is used for the treatment of invasive fungal infections with a near-term focus on those caused by Cryptococcus and Candida. The ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The ATI-1503 is a drug discovery program builds off the molecular structure of negamycin, a naturally occurring compound that can kill Gram-negative bacteria. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole. Metronidazole is a front-line antibiotic for the treatment of anaerobic bacterial and parasitic infections. The Favipiravir is an oral covid-19 antiviral candidate.
